Skip to main content
Delfa

← All trials/NCT07506369

APP

RecruitingPhase NA

Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

Asset

Pramlintide

Amylin analog

Listed sites

1

Recruiting sites

1

Estimated enrollment

18

Study population

Healthy volunteers

Eligibility highlights

•BMI 18-27•Male

Primary endpoint

•Food intake

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07506369
Org study IDH-25083528

Timeline

Milestones

Study first posted2026-04-01actual
Last update posted2026-04-01actual
Study start2026-04estimated (month precision)
Primary completion2026-10estimated (month precision)
Study completion2028-10estimated (month precision)

Assets

Investigational agents

Pramlintide

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Male
•Age between 18 and 65 years at the time of inclusion
•Body mass index 18-27 kg/m2
•Fat percentage < 20%
•Informed oral and written consent

Exclusion criteria

•Anaemia (haemoglobin below normal range)
•History of hepatobiliary and/or gastrointestinal disorder(s)
•Kidney disease
•Previous gastric or intestinal resection, cholecystectomy and/or any major intra- abdominal surgery (including bariatric surgery)
•Previous pancreatic disease and/or neoplasia
•Regular tobacco smoking and/or use of other nicotine products
•Glycated haemoglobin (HbA1c) ≥48 and/or type 1 diabetes or type 2 diabetes requiring medical treatment
•Initiation of special diets, lifestyle changes and/or weight loss >5% of total body weight within three months prior to or during study period
•Any physical or psychological condition or ongoing medication the investigator group suspects would interfere with trial participation

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL
1
Other clinical outcomes
1
Other (unclassified)
1

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Sensations of hunger, satiety, fullness, prospective food intake, nausea, thirst, comfort

Time frame:-30 to 330 minutes

descriptive

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint/low confidence

Composite appetite score

Time frame:-30 min to 330

descriptive, improvement

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Food intake

Time frame:300 to 330 minutes

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.